<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">zdor</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы здоровья и экологии</journal-title><trans-title-group xml:lang="en"><trans-title>Health and Ecology Issues</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2220-0967</issn><issn pub-type="epub">2708-6011</issn><publisher><publisher-name>Gomel State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51523/2708-6011.2023-20-2-03</article-id><article-id custom-type="elpub" pub-id-type="custom">zdor-2545</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>Определение уровня лептина и растворимого рецептора лептина у пациенток с гиперпластическими процессами эндометрия</article-title><trans-title-group xml:lang="en"><trans-title>Measurement of leptin and soluble leptin receptor levels in patients with endometrial hyperplastic processes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8465-9368</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лызикова</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyzikova</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лызикова Юлия Анатольевна, д.м.н., доцент,  профессор кафедры акушерства и гинекологии с  курсом ФПКиП</p><p>Гомель</p></bio><bio xml:lang="en"><p>Yuliya A. Lyzikova, Doctor of Medical Sciences,  Associate Professor, Professor of the Department of  Obstetrics and Gynecology with the course of FPDR</p><p>Gomel</p></bio><email xlink:type="simple">lyzikovayulia@yandex.by</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2606-7006</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Смирнова Марина Владимировна, врач ультразвуковой диагностики</p><p>Гомель</p></bio><bio xml:lang="en"><p>Maryna V. Smirnova, Ultrasound Diagnostics Doctor</p><p>Gomel</p></bio><email xlink:type="simple">marinasmirnova6793@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Гомельский государственный медицинский  университет</institution></aff><aff xml:lang="en"><institution>Gomel State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Гомельская городская клиническая больница № 2</institution></aff><aff xml:lang="en"><institution>Gomel City Clinical Hospital № 2</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>10</day><month>07</month><year>2023</year></pub-date><volume>20</volume><issue>2</issue><fpage>22</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лызикова Ю.А., Смирнова М.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Лызикова Ю.А., Смирнова М.В.</copyright-holder><copyright-holder xml:lang="en">Lyzikova Y.A., Smirnova M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.gsmu.by/jour/article/view/2545">https://journal.gsmu.by/jour/article/view/2545</self-uri><abstract><p>Цель исследования. Оценить уровни лептина и растворимого рецептора лептина у пациентов с гиперпластическими процессами эндометрия.Материалы и методы. В исследование включено 90 пациентов, из них 70 с гиперпластическими процессами эндометрия составили основную группу, 20 с морфологически нормальным эндометрием включены в группу сравнения. Методом иммуноферментного анализа в сыворотке крови определена концентрация лептина и растворимого рецептора лептина, изучены клинико-анамнестические характеристики заболевания.Результаты. При сравнении уровня лептина в сыворотке крови не получено значимых различий между группами: в основной группе уровень гормона составил 6,01 (3,64; 7,50) нг/мл, в группе сравнения — 6,44 (3,55; 10,11) нг/мл (z = 0,61, p = 0,54). Уровень растворимого рецептора лептина у пациенток основной группы был значимо ниже и составил 8531 (5697; 15895) пг/мл, в группе сравнения — 16181 (10696; 20251) пг/мл (z = 2,614, p = 0,008).Заключение. Для пациентов с гиперпластическими процессами эндометрия характерно снижение уровня растворимого рецептора лептина, в то время как уровень лептина не имеет значимых различий по сравнению с аналогичным показателем у пациенток без патологии эндометрия. Выявленное состояние обуславливает дефект передачи сигнала от лептинового рецептора и снижение транспорта гормона, приводящее к нарушению биологического действия лептина. Установленный уровень растворимого рецептора лептина &lt; 14769 пг/мл, в комплексе с ультразвуковым методом исследования, позволит повысить эффективность диагностических мероприятий по выявлению гиперпластических процессов эндометрия.</p></abstract><trans-abstract xml:lang="en"><p>Objective. To measure leptin and soluble leptin receptor levels in patients with endometrial hyperplastic processes.Materials and methods. 90 patients were included in the study, 70 with hyperplastic endometrial processes made up the main group, 20 with morphologically normal endometrium were included in the comparison group. The concentration of leptin and the soluble leptin receptor in the blood serum was measured by the method of enzyme immunoassay, the clinical and anamnestic characteristics of the disease were studied Results. There were no significant differences between the groups when comparing serum leptin levels: in the study group, the hormone level was 6,01 (3,64;7,50) ng/ml, in the comparison group — 6,44 (3,55;10,11) ng/ml (z = 0,61, p = 0,54). The level of soluble leptin receptor was significantly lower in patients in the main group and was 8531 (5697; 15895) ng/ml, and 16181 (10696; 20251) ng/ml in the comparison group (z = 2.614, p = 0.008).Conclusion. Patients with endometrial hyperplastic processes are characterized by a decreased level of the soluble leptin receptor, whereas a leptin level has no significant differences compared to those in patients without endometrial pathology. The identified condition causes a defect in the signal transmission from the leptin receptor and a decrease in the hormone transport, leading to a disruption of the biological action of leptin. The established level of soluble leptin receptor &lt; 14769 pg/ml, in combination with ultrasound examination, will increase the efficiency of diagnostic measures to detect endometrial hyperplastic processes.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гиперпластические процессы эндометрия</kwd><kwd>лептин</kwd><kwd>растворимый рецептор лептина</kwd></kwd-group><kwd-group xml:lang="en"><kwd>endometrial hyperplastic processes</kwd><kwd>leptin</kwd><kwd>soluble leptin receptor</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Научная работа выполнена за счет средств инновационного фонда Гомельского областного исполнительного комитета в рамках проекта «Разработать и внедрить метод персонализированного лечения гиперпластических процессов эндометрия женщин», № госрегистрации 20201765 от 05.11.2020 г.</funding-statement><funding-statement xml:lang="en">The study was sponsored by the Innovation Fund of the Gomel Regional Executive Committee within the framework of the project “To develop and implement a method of personalized treatment of endometrial hyperplastic processes in women”, state registration number 20201765 of 05.11.2020.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">El-Hamed AT, Mahmoud SA, Soliman AA, El-Yasergy DF. Immunohistochemical expression of “HE4” in endometrial hyperplasia versus endometrial endometrioid carcinoma. Open Access Macedonian Journal of Medical Sciences. 2021;9:669-675. DOI: https://doi.org/10.3889/oamjms.2021.6189</mixed-citation><mixed-citation xml:lang="en">El-Hamed AT, Mahmoud SA, Soliman AA, El-Yasergy DF. Immunohistochemical expression of “HE4” in endometrial hyperplasia versus endometrial endometrioid carcinoma. Open Access Macedonian Journal of Medical Sciences. 2021;9:669-675. DOI: https://doi.org/10.3889/oamjms.2021.6189</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Elias K, Webb DL, Tartera HOD, Hellstrom PM, Sundbom M. Impact of biliopancreatic diversion with duodenal switch on glucose homeostasis and gut hormones and their correlations with appetite. Surgery for obesity and related diseases. 2022;18:1345-1356. DOI: https://doi.org/10.1016/j.soard.2022.08.010</mixed-citation><mixed-citation xml:lang="en">Elias K, Webb DL, Tartera HOD, Hellstrom PM, Sundbom M. Impact of biliopancreatic diversion with duodenal switch on glucose homeostasis and gut hormones and their correlations with appetite. Surgery for obesity and related diseases. 2022;18:1345-1356. DOI: https://doi.org/10.1016/j.soard.2022.08.010</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Su YH, Wu YZ, Ann DK, Chen JL, Kuo CY. Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer. DOI: https://doi.org/10.1038/s41419-023-05576-8</mixed-citation><mixed-citation xml:lang="en">Su YH, Wu YZ, Ann DK, Chen JL, Kuo CY. Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer. DOI: https://doi.org/10.1038/s41419-023-05576-8</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J, Lai F, Hou Y, Zheng R. Leptin signaling and leptin resistance. Medicine Review. 2022;2(4):363-384. DOI: https://doi.org/10.1515/mr-2022-0017</mixed-citation><mixed-citation xml:lang="en">Liu J, Lai F, Hou Y, Zheng R. Leptin signaling and leptin resistance. Medicine Review. 2022;2(4):363-384. DOI: https://doi.org/10.1515/mr-2022-0017</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Casado ME, Collado-Perez R, Frago LR, Barrios V. Recent advances in the knowledge of the mechanisms of leptin physiology and actions in neurological and metabolic pathologies. International Journal of Molecular Sciences. 2023.24(2):1422. DOI: https://doi.org/10.3390/ijms24021422</mixed-citation><mixed-citation xml:lang="en">Casado ME, Collado-Perez R, Frago LR, Barrios V. Recent advances in the knowledge of the mechanisms of leptin physiology and actions in neurological and metabolic pathologies. International Journal of Molecular Sciences. 2023.24(2):1422. DOI: https://doi.org/10.3390/ijms24021422</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mendez-Lopez LF, Zavala-Pompa A, Cortes-Gutierrez EI, Cerda-Flores RM, Davila-Rodriguez MI. Leptin receptor expression during the progression of endometrial carcinoma is correlated with estrogen and progesterone receptors. Archives of Medical Science. 2017;13(1):228-235. DOI: https://doi.org/10.5114/aoms.2017.64721</mixed-citation><mixed-citation xml:lang="en">Mendez-Lopez LF, Zavala-Pompa A, Cortes-Gutierrez EI, Cerda-Flores RM, Davila-Rodriguez MI. Leptin receptor expression during the progression of endometrial carcinoma is correlated with estrogen and progesterone receptors. Archives of Medical Science. 2017;13(1):228-235. DOI: https://doi.org/10.5114/aoms.2017.64721</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Рыжов Ю.Р., Шпаков А.О., Гзгзян А.М. Роль лептина в регуляции репродуктивной системы и перспективы его использования во вспомогательных репродуктивных технологиях. Проблемы репродукции. 2020;(2):53-56. DOI: https://doi.org/10.17116/repro20202602153</mixed-citation><mixed-citation xml:lang="en">Ryzhov JR, Shpakov AO, Gzgzyan AM. Leptin role in reproductive system regulation and its perspectives in assisted reproductive technologies. Russian Journal of Human Reproduction. 2020;26(2):53-61. (In Russ.). DOI: https://doi.org/10.17116/repro20202602153</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">El-AttarAA, Ibrahim OM, Alhassanin SA, EssaES, Mostafa TM. Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. European Journal of Clinical Pharmacology. 2023;79:299-309. DOI: https://doi.org/10.1007/s00228-022-03444-6</mixed-citation><mixed-citation xml:lang="en">El-AttarAA, Ibrahim OM, Alhassanin SA, EssaES, Mostafa TM. Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. European Journal of Clinical Pharmacology. 2023;79:299-309. DOI: https://doi.org/10.1007/s00228-022-03444-6</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Su S, Yin L. Application of Pelvic Magnetic Resonance Imaging Scan Combined with Serum Pyruvate Kinase Isozyme M2, Neutrophil Gelatinase-Associated Lipocalin, and Soluble Leptin Receptor Detection in Diagnosing Endometrial Carcinoma. Contrast Media Mol Imaging. 2022. 21. DOI: https://doi.org/10.1155/2022/7197505</mixed-citation><mixed-citation xml:lang="en">Su S, Yin L. Application of Pelvic Magnetic Resonance Imaging Scan Combined with Serum Pyruvate Kinase Isozyme M2, Neutrophil Gelatinase-Associated Lipocalin, and Soluble Leptin Receptor Detection in Diagnosing Endometrial Carcinoma. Contrast Media Mol Imaging. 2022. 21. DOI: https://doi.org/10.1155/2022/7197505</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rodrigo С, Tennekoon KH, Karunanayake EH, De Silva K, Amarasinghe I, Wijayasir A. Circulating leptin, soluble leptin receptor, free leptin index, visfatin and selected leptin and leptin receptor genepolymorphisms in sporadic breast cancer. Endocrine journal. 2017;64(4):393-401. DOI: https://doi.org/10.1507/endocrj.EJ16-0448</mixed-citation><mixed-citation xml:lang="en">Rodrigo С, Tennekoon KH, Karunanayake EH, De Silva K, Amarasinghe I, Wijayasir A. Circulating leptin, soluble leptin receptor, free leptin index, visfatin and selected leptin and leptin receptor genepolymorphisms in sporadic breast cancer. Endocrine journal. 2017;64(4):393-401. DOI: https://doi.org/10.1507/endocrj.EJ16-0448</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
